The TrkB agonist 7,8‐dihydroflavone restored progression of autophagy in a preclinical model of Parkinson's disease (Zuo et al., 2021), and the TrkB antagonist K252a decreased autophagosome formation in rat hippocampus (Liu et al., 2020). Here, NTRK2 is linked to Parkinson disease.